Journal of Applied Physiology, Vol 78, Issue 1 225-231, Copyright © 1995 by American Physiological Society

ARTICLES

Protective effect of mepacrine on hypoxia-reoxygenation-induced acute lung injury in rats

C. Y. Shen, D. Wang, M. L. Chang and K. Hsu
Department of Medicine, Tri-Service General Hospital, Taiwan, Republic of China.

Mepacrine, a cell membrane stabilizer and inhibitor of phospholipase A2 (PLA2), exerts a protective effect on ischemia-reperfusion injury in heart; however, its effect in lungs has not been examined. This study aimed to determine whether mepacrine pretreatment attenuates ischemia-reperfusion lung injury simulated by hypoxia reoxygenation and to identify possible mechanisms for such protection. Acute lung injury was induced in Sprague-Dawley rats by ventilation with 5% CO2-95% N2 and 5% CO2-95% air. Pretreatment with 0.06 mM mepacrine significantly attenuated the acute lung injury. Capillary filtration coefficient, lung weight gain, and protein concentration of lung lavage fluid were significantly lower in mepacrine-treated rats than in rats exposed to hypoxia reoxygenation alone. Steroid dexamethasone, another potential PLA2 inhibitor, had almost no protective effect. Mepacrine but not dexamethasone caused dose-dependent attenuation of the increase in leukocyte chemiluminescence produced by exposure to phorbol myristate acetate. Mepacrine also dose-dependently inhibited production of tumor necrosis factor-alpha (TNF-alpha) by human monocytes; dexamethasone was much less effective in decreasing TNF-alpha production. We conclude that mepacrine but not dexamethasone can significantly attenuate a hypoxia-reoxygenation-induced injury of the lung. This protective effect of mepacrine may not be the result of its inhibition of PLA2 but rather of its downregulation of oxygen radical production by circulating or resident leukocytes or its attenuation of TNF-alpha production by macrophages.

This article has been cited by other articles:

				Y. A. B. Reyes, T. Shimoyama, H. Akamatsu, and M. Sunamori MCI-186 (edaravone), a free radical scavenger, attenuates ischemia-reperfusion injury and activation of phospholipase A2 in an isolated rat lung model after 18 h of cold preservation Eur. J. Cardiothorac. Surg., March 1, 2006; 29(3): 304 - 311. [Abstract] [Full Text] [PDF]

				S. J. Kao, D. Wang, D. Y.-W. Yeh, K. Hsu, Y. H. Hsu, and H. I. Chen Static Inflation Attenuates Ischemia/Reperfusion Injury in an Isolated Rat Lung In Situ Chest, August 1, 2004; 126(2): 552 - 558. [Abstract] [Full Text] [PDF]

				M. de Perrot, M. Liu, T. K. Waddell, and S. Keshavjee Ischemia-Reperfusion-induced Lung Injury Am. J. Respir. Crit. Care Med., February 15, 2003; 167(4): 490 - 511. [Abstract] [Full Text] [PDF]

				C.-H. CHIANG, K. WU, C.-P. YU, H.-C. YAN, W.-C. PERNG, and C.-P. WU Hypothermia and Prostaglandin E1 Produce Synergistic Attenuation of Ischemia-Reperfusion Lung Injury Am. J. Respir. Crit. Care Med., October 1, 1999; 160(4): 1319 - 1323. [Abstract] [Full Text]

				W. O. Carter, C. Bull, E. Bortolon, L. Yang, G. J. Jesmok, and R. H. Gundel A murine skeletal muscle ischemia-reperfusion injury model: differential pathology in BALB/c and DBA/2N mice J Appl Physiol, November 1, 1998; 85(5): 1676 - 1683. [Abstract] [Full Text] [PDF]

				X.-W. JIANG, K. KAMBARA, N. GOTOH, K. NISHIGAKI, and H. FUJIWARA Effects of Low-Dose Beraprost Sodium, a Stable Prostaglandin I2 Analogue, on Reperfusion Injury to Rabbit Lungs Am. J. Respir. Crit. Care Med., November 1, 1998; 158(5): 1669 - 1675. [Abstract] [Full Text] [PDF]

				C.-H. Chiang, K. Hsu, H.-C. Yan, H.-J. Harn, and D.-M. Chang PGE1, dexamethasone, U-74389G, or Bt2-cAMP as an additive to promote protection by UW solution in I/R injury J Appl Physiol, August 1, 1997; 83(2): 583 - 590. [Abstract] [Full Text] [PDF]